Spatial Approximations between Residues 6 and 12 in the Amino-terminal Region of Glucagon-like Peptide 1 and Its Receptor
暂无分享,去创建一个
Laurence J Miller | Maoqing Dong | L. Miller | M. Dong | D. Pinon | Delia I Pinon | Quan Chen | Quan Chen
[1] B. Wulff,et al. Different domains of the glucagon and glucagon‐like peptide‐1 receptors provide the critical determinants of ligand selectivity , 2003, British journal of pharmacology.
[2] G. Bitan,et al. Photoaffinity Cross-linking Identifies Differences in the Interactions of an Agonist and an Antagonist with the Parathyroid Hormone/Parathyroid Hormone-related Protein Receptor* , 2000, The Journal of Biological Chemistry.
[3] L. Miller,et al. Demonstration of a Direct Interaction between Residue 22 in the Carboxyl-terminal Half of Secretin and the Amino-terminal Tail of the Secretin Receptor Using Photoaffinity Labeling* , 1999, The Journal of Biological Chemistry.
[4] L. Suva,et al. Direct mapping of an agonist-binding domain within the parathyroid hormone/parathyroid hormone-related protein receptor by photoaffinity crosslinking. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[5] M. Chorev,et al. Mapping the bimolecular interface of the parathyroid hormone (PTH)-PTH1 receptor complex: spatial proximity between Lys(27) (of the hormone principal binding domain) and leu(261) (of the first extracellular loop) of the human PTH1 receptor. , 2000, Biochemistry.
[6] P. Hajduk,et al. Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS , 2007, Proceedings of the National Academy of Sciences.
[7] Byung-Kwon Lee,et al. The mid-region of parathyroid hormone (1-34) serves as a functional docking domain in receptor activation. , 2006, Biochemistry.
[8] R. Abagyan,et al. Molecular Approximations between Residues 21 and 23 of Secretin and Its Receptor: Development of a Model for Peptide Docking with the Amino Terminus of the Secretin Receptor , 2007, Molecular Pharmacology.
[9] A. Couvineau,et al. The N-Terminal Parts of VIP and Antagonist PG97–269 Physically Interact with Different Regions of the Human VPAC1 Receptor , 2008, Journal of Molecular Neuroscience.
[10] M. Beyermann,et al. Photoaffinity cross-linking of the corticotropin-releasing factor receptor type 1 with photoreactive urocortin analogues. , 2005, Biochemistry.
[11] L. Miller,et al. Molecular Approximation between a Residue in the Amino-terminal Region of Calcitonin and the Third Extracellular Loop of the Class B G Protein-coupled Calcitonin Receptor* , 2004, Journal of Biological Chemistry.
[12] L. Miller,et al. Multiple Extracellular Loop Domains Contribute Critical Determinants for Agonist Binding and Activation of the Secretin Receptor* , 1996, The Journal of Biological Chemistry.
[13] D. Drucker,et al. International Union of Pharmacology. XXXV. The Glucagon Receptor Family , 2003, Pharmacological Reviews.
[14] L. Miller,et al. Critical Contributions of Amino-terminal Extracellular Domains in Agonist Binding and Activation of Secretin and Vasoactive Intestinal Polypeptide Receptors. STUDIES OF CHIMERIC RECEPTORS (*) , 1995, The Journal of Biological Chemistry.
[15] R. Rudolph,et al. Passing the baton in class B GPCRs: peptide hormone activation via helix induction? , 2009, Trends in biochemical sciences.
[16] Laurence J Miller,et al. Molecular Basis of Glucagon-like Peptide 1 Docking to Its Intact Receptor Studied with Carboxyl-terminal Photolabile Probes* , 2009, The Journal of Biological Chemistry.
[17] R. Rudolph,et al. In vitro folding, functional characterization, and disulfide pattern of the extracellular domain of human GLP-1 receptor. , 2002, Biophysical chemistry.
[18] T. Lybrand,et al. Direct Identification of a Distinct Site of Interaction between the Carboxyl-terminal Residue of Cholecystokinin and the Type A Cholecystokinin Receptor Using Photoaffinity Labeling* , 1997, The Journal of Biological Chemistry.
[19] Toru Egashira,et al. Five missense mutations in glucagon-like peptide 1 receptor gene in Japanese population. , 2004, Diabetes research and clinical practice.
[20] Lotte Bjerre Knudsen,et al. Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor* , 2009, The Journal of Biological Chemistry.
[21] D. Drucker,et al. Glucagon and glucagon-like peptide receptors as drug targets. , 2006, Current pharmaceutical design.
[22] H. Jüppner,et al. Multiple Sites of Contact between the Carboxyl-terminal Binding Domain of PTHrP-(1–36) Analogs and the Amino-terminal Extracellular Domain of the PTH/PTHrP Receptor Identified by Photoaffinity Cross-linking* , 2001, Journal of Biological Chemistry.
[23] L. B. Knudsen,et al. Structure-activity studies of glucagon-like peptide-1. , 1994, The Journal of biological chemistry.
[24] L. Miller,et al. Juxtamembranous Region of the Amino Terminus of the Family B G Protein-coupled Calcitonin Receptor Plays a Critical Role in Small-molecule Agonist Action* , 2009, The Journal of Biological Chemistry.
[25] R. Abagyan,et al. Spatial Approximation between Secretin Residue Five and the Third Extracellular Loop of Its Receptor Provides New Insight into the Molecular Basis of Natural Agonist Binding , 2008, Molecular Pharmacology.
[26] L. Suva,et al. Parathyroid Hormone-Receptor Interactions Identified Directly by Photocross-linking and Molecular Modeling Studies* , 1998, The Journal of Biological Chemistry.
[27] D. Drucker,et al. Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.
[28] M. Wheeler,et al. Characterization of glucagon-like peptide-1 receptor-binding determinants. , 2000, Journal of molecular endocrinology.
[29] A. Couvineau,et al. Peptide Agonist Docking in the N-terminal Ectodomain of a Class II G Protein-coupled Receptor, the VPAC1 Receptor , 2006, Journal of Biological Chemistry.
[30] L. Miller,et al. Intrinsic photoaffinity labeling of native and recombinant rat pancreatic secretin receptors. , 1993, Gastroenterology.
[31] R. Riek,et al. Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand , 2007, Proceedings of the National Academy of Sciences.
[32] D. Donnelly,et al. The glucagon‐like peptide‐1 receptor binding site for the N‐terminus of GLP‐1 requires polarity at Asp198 rather than negative charge , 2002, FEBS letters.
[33] K. Eckart,et al. Structure/activity characterization of glucagon-like peptide-1. , 1994, European journal of biochemistry.
[34] T. Gardella,et al. Identification of a contact site for residue 19 of parathyroid hormone (PTH) and PTH-related protein analogs in transmembrane domain two of the type 1 PTH receptor. , 2003, Molecular endocrinology.
[35] A. Piserchio,et al. Characterization of parathyroid hormone/receptor interactions: structure of the first extracellular loop. , 2000, Biochemistry.
[36] Tsutomu Kouyama,et al. Crystal structure of squid rhodopsin , 2008, Nature.
[37] H. Xu,et al. Molecular Recognition of Corticotropin-releasing Factor by Its G-protein-coupled Receptor CRFR1* , 2008, Journal of Biological Chemistry.
[38] H. Xu,et al. Molecular recognition of parathyroid hormone by its G protein-coupled receptor , 2008, Proceedings of the National Academy of Sciences.
[39] R. Rudolph,et al. The N-terminal fragment of human parathyroid hormone receptor 1 constitutes a hormone binding domain and reveals a distinct disulfide pattern. , 2000, Biochemistry.
[40] L. Miller,et al. Use of N,O-bis-Fmoc-D-Tyr-ONSu for introduction of an oxidative iodination site into cholecystokinin family peptides. , 2009, International journal of peptide and protein research.
[41] T. Lybrand,et al. Spatial Approximation between the Amino Terminus of a Peptide Agonist and the Top of the Sixth Transmembrane Segment of the Secretin Receptor* , 2004, Journal of Biological Chemistry.
[42] C. Strader,et al. The amino terminal domain of the glucagon-like peptide-1 receptor is a critical determinant of subtype specificity. , 1996, Receptors & channels.
[43] Renxiao Wang,et al. Molecular modeling of the three-dimensional structure of GLP-1R and its interactions with several agonists , 2009, Journal of molecular modeling.
[44] S. Hoare,et al. Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. , 2005, Drug discovery today.
[45] L. Miller,et al. Importance of the Amino Terminus in Secretin Family G Protein-coupled Receptors , 2004, Journal of Biological Chemistry.
[46] A. Couvineau,et al. Aspartate 196 in the first extracellular loop of the human VIP1 receptor is essential for VIP binding and VIP-stimulated cAMP production. , 1997, Biochemical and biophysical research communications.
[47] A. Kopin,et al. A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness , 2005, Regulatory Peptides.
[48] Y. Cao,et al. The amino-terminal fragment of the adenylate cyclase activating polypeptide (PACAP) receptor functions as a high affinity PACAP binding domain. , 1995, Biochemical and biophysical research communications.
[49] D Rodbard,et al. Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.
[50] A. Couvineau,et al. The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics. , 2008, Molecular endocrinology.
[51] Kjeld Madsen,et al. Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain* , 2008, Journal of Biological Chemistry.
[52] L. Miller,et al. Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptors. , 2008, Molecular endocrinology.
[53] J. Vilardaga,et al. The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors , 1996, Peptides.
[54] L. Miller,et al. Relationship Between Native and Recombinant Cholecystokinin Receptors: Role of Differential Glycosylation , 1996, Pancreas.
[55] D. Drucker. Biologic actions and therapeutic potential of the proglucagon-derived peptides , 2005, Nature Clinical Practice Endocrinology &Metabolism.
[56] R. Riek,et al. NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[57] D. Donnelly,et al. Met-204 and Tyr-205 are together important for binding GLP-1 receptor agonists but not their N-terminally truncated analogues. , 2004, Protein and peptide letters.
[58] Angela Wittelsberger,et al. Mapping peptide hormone-receptor interactions using a disulfide-trapping approach. , 2008, Biochemistry.